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Abstract 
Breast cancer is a common malignancy and a lifetime risk among females worldwide. 
Interestingly, it has been observed that Hsp90 is overexpressed in many breast cancer cells. 
Hsp90 is a highly conserved molecular chaperone and is having ATP dependent functions that 
involve stress response, homeostatic control, folding, stabilization, activation, and assembly of 
wide range of client proteins including p53 in various biological processes. Hsp90 inhibition has 
been reported to be a therapeutic approach in breast cancer. 
In the present investigation, Hsp90 and its Hsp complex (Hsp70, Hsp40) has been docked with 
wild type p53 and mutant p53 with the help of Hex 6.3 docking software. The results showed 
that while Hsp90 alone has high affinity to bind with wild type p53, its affinity becomes high for 
mutant p53 when it is associated with multi-chaperone complex. In order to inhibit Hsp90 a wide 
range of ligands were selected and docked by Hex 6.3 keeping ATP as control. Geldanamycin 
having binding energy  -315.36 kcal/mol showed highest inhibition among all. The ligplot 1.3.6 
analysis confirmed the involvement of four residues Asp93, Phe138, Lys58, and Thr184 at the 
binding interface. Due to poor solubility and cytotoxicity results, Geldanamycin was modified 
into ten analogues using Marvinsketch tool 5.9.1 
While Analogue 2 found to be the best Hsp90 inhibitor by Hex 6.3 docking, Analogue 9 however 
observed to be the best when docked by Autodock 4.0 software. Further docking of this 
inhibitory complex with mutant p53 by Hex 6.3 elucidated the effect of inhibition. Inhibited 
Hsp90 showed less binding affinity towards mutant p53 depicts the conformational changes upon 
inhibition. 
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1.1Introduction 
Normally cell growth takes place in a control and co-ordinate manner. But sometimes due to 
external factors cells grow uncontrollably. And this uncontrolled growth leads to formation of 
tumor. The tumor may be a benign one or a malignant one. Benign ones do not form cancer 
while malignant ones not only form cancer but also metastasize to other parts of the body that 
lead to death. All this happen because of disturbances in cell cycle and regulatory pathways. The 
reason may be genetic mutation, functional aberration in cell cycle, effect of environmental 
factor and age factor. There are many different types of cancer affecting different parts of body, 
most of which are termed according to the place of origin. 
1.1.1Breast cancer 
Cancer is the main cause of death worldwide, approximately 7.6 million deaths (around 13% of 
all deaths) in 2008, with an expected 13.1 million deaths in 2030. And breast cancer covers 
22.9% of all cancers in women. In 2008, breast cancer caused 13.7% of cancer deaths in women 
all over the world. There is a lifetime risk of developing breast cancer. The occurrence of breast 
cancer in India is on the escalation and is quickly becoming the number one cancer in females. 
The importance of the situation is apparent after working through current data from Indian 
Council of Medical Research (ICMR). It is testified that one in 22 women in India is expected to 
suffer from breast cancer during her lifespan. (Ferlay, J. et al 2007).  
 
Hanahan and Weinberg   (Hanahan and Weinberg et al 2000) stated that genetic disorder allows 
a cell to procure six characteristics that are specific to most cancers. Those are (i) self-capability 
in cell growth signaling  (ii)non-responsive to anti-growth signaling (iii) ability to evade 
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apoptosis (iv) persistent angiogenesis (v) tissue invasion and metastasis and (vi) indefinite 
replicative potential. 
The genetic instability of cancer cells allow them to escape the molecular targeting of signalling 
pathway, which makes them insensitive to targeted therapeutics. Thus continuous attack on 
multiple points or nodes of a cancer cell’s network of overlapping signalling pathways should be 
affected than the inhibition of one or a few individual signalling nodes.  
The maximum oncoproteins and their web are entangled with hsp90 molecular chaperone.  
1.1.2 HSP90 
Heat shock protein 90 (Hsp90), a molecular chaperone that plays important role in folding, 
stabilizing, activating and maintaining the conformational integrity of its client proteins through 
its ATPase activity. Some of its client proteins are Her2, Raf-1, Akt, Cdk4, polo-1 kinase, B-Raf, 
mutant p53, Bcr-Abl and are connected with cell regulation and signalling. Cancer cells use the 
Hsp90 chaperone to protect the mutated oncoproteins from misfolding and proteasomal 
degradation. It is found that Hsp90 ATPase activity is up regulated nearly 100 fold in cancer 
cells. And the reason may be the up regulation of its function 
Hsp90 is a member of superfamily (includes DNA gyrase, Histidine kinase and DNA mismatch 
pair) that contains an ATP binding pocket which is different from ATP binding cleft of protein 
kinases. The evolutionary conserved chaperone structure consists of three domains. These 
domains are composed of nearly 732 amino acids. It has two isomers α and β, mainly present in 
cytosol. The N –terminal domain is an amino terminal domain that contains a fold known as 
bergerat fold which is having the ATP and drug binding site. The middle domain is having a co-
chaperone interacting motifs that provide docking sites for client proteins and co-chaperones 
which play a part in forming the active ATPase. The c-terminal domain is the carboxyl terminal 
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domain that is having a dimerization motif, which is a second drug binding region and site of 
interaction of other  co-chaperones. Dimerization of Hsp90 monomer via c-terminus is crucial 
for chaperoning function. After dimerization in its open state bind to ATP molecule hence 
preceding the attachment of co-chaperones and client protein. Hence inhibiting the ATPase cycle 
would interfere with the chaperoning function directly. The client protein those are in mutated 
form would go for proteasomal degradation, if the support thread of hsp90 vanishes. 
1.1.3 p53 
One of the most important client proteins of Hsp90 is p53, also known as “the guardian of the 
genome”. It is a phosphoprotein that contains 393 amino acids and four domains .In normal cells 
p53 expression is low and which is responsible for cell cycle, DNA repair and Apoptosis. The 
major regulator of p53 is Mdm2, which is responsible for triggering its degradation. But the 
mutant form of p53 which involve in cell malignancy is found to bind with hsp90 strongly and 
escape the proteasomal degradation pathway. This result in high level of p53 and further it lead 
to increase the level of hsp90, which interfere with the normal metabolism of the cell. Therefore 
hsp90 is pursued as a promising target for cancer therapy. 
Small molecular hsp90 inhibitors bind to ATP binding pocket that cause the inhibition of the  
catalytic cycle  of hsp90 in the ADP bound structure, leading to the inhibition of chaperone 
activity. This result in proteasomal degradation of oncoproteins, promotes cell cycle arrest and 
consequent apoptosis. Inhibition of hsp90 function is effective in killing cancer cells, which are 
resistant to therapy as kinase inhibitors. Thus Hsp90 is a promising target in cancer therapy and 
with the development of Hsp90-inhibitory agents in neurodegenerative diseases and pathogenic 
resistance (i.e., viral, fungal, bacterial) is following behind. 
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There are now 13 inhibitors undergoing clinical evaluation and 23 active ones for oncology 
trials, with many others following in late stage IND (Investigational New Drug) evaluation and 
pre-clinical evaluation. While the interest in inhibitors spreading fast, the knowledge on the 
target lagging behind. It is known that when all inhibitors in advanced stage binding to its N-
terminal binding site regulatory pocket, evidence showed some important distinction in the 
invitro and invivo behavior. The differences are the kinetics of client protein modulation and 
invivo pharmacodynamics, both of which have a strong effect on the clinical efficacy and 
therapeutic window. In addition it is important to identify tumor and disease specific Hsp90 
clients and implement in clinic as molecular markers to get a proof that the target Hsp90 is 
inhibited. The cost of successful anticancer drug development to approval has scaled to more 
than 800 million dollar. Most molecules are known to inhibit Hsp90 function. Among which 
Geldanamycin was the first identified Hsp90 inhibitor and as such has served a central role in the 
study of hsp90 biology. For these findings, Computational tools and Bioinformatics softwares 
are needed. In this era Insilico approach reduces half of the cost of the research work 
1.1.4 Bioinformatics and Computational Biology 
 Now-a-days the enhancement of Bioinformatics and Cheminformatics is paving the way for 
easy drug designing. Computational biology and Bioinformatics have the potential to speed up 
drug discovery processes, reducing the costs of the processes and changing the way the drugs are 
designed. Rational drug design facilitates and speeds up the drug designing processes that 
involves various method of identifying novel compounds. One advanced method is the docking 
of the drug molecule or ligand or inhibitor with the target. The site where the drug binds is 
known to the site of action, which is responsible for the pharmaceutical effect is the target. 
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Docking is the method by which two molecules bind to each other in 3D space. In addition, 
regression based or knowledge based scoring functions can be useful to compute the free 
enthalpy of ligand binding. There are various tools, softwares and servers meant for docking 
calculations. They may be rigid, flexible, and semi flexible docking. There are different 
databases store macromolecular 3D structure and ligand structure, which are extracted from 
NMR co-ordinates used for docking and simulations. Thus computational biology or In Silico 
approach is developing day by day with refinement. It is becoming a promising field and with 
the help of this the time and cost of biological work related to drug discovery, molecular 
interaction is reducing. 
 
 
1.2 Objective 
 To investigate the binding affinity of the interaction between Hsp90 and p53. 
 To identify the amino acid residues located at the binding interface. 
 To design novel Geldanamycin analogues as Hsp90-inhibitors. 
 To analyze the effect of Hsp90 inhibition of various novel inhibitors on the binding 
affinity between Hsp90 and p53. 
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1.3 Plan of Work 
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Autodock 4.0 and Ligplot analysis. 
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2. Literature review 
2.1 Heat shock proteins(also known as molecular chaperones) 
When a cell experiences environmental stress, either its cycle stops, or slows down its original 
functions, such as transportation, DNA, RNA and protein synthesis.  However, a set of proteins, 
called stress proteins, which are mainly expressed under these adverse conditions of stress 
response in rise in the outside temperature, called heat shock proteins. 
 In 1962 Feruccio Ritossa discovered the heat shock response, who observed an amplification 
of special sections of Drosophila melanogaster chromosomes (heat shock puffs) when heat 
treatment was given to the flies. 
Most of the heat shock proteins are molecular chaperones 
In 1996 Hartl defined chaperone as “proteins that bind to and stabilize an otherwise unstable 
form of other protein and, by exact binding and release, enable its correct fate in vivo: be it 
folding, oligomer assembly, transportation to a certain subcellular compartment, or removal by 
degradation”  
In 1996 Multhoff and Hightower et al discovered the expression of heat shock proteins on 
cancer cell surface. 
2.2 Heat Shock Protein 90KDa (HSP90) 
Hsp90 is a cytosolic protein, nearly present 1-2% in the cytosol. Its concentration varies 
depending on cells. (Lai et al 1984, Nollen and Morimoto 2002, Ghaemmaghami et al 2003). It 
is over expressed in cancer cells and estimated to be 2.8% in colon cancer cells. (Neckers 2002, 
Whitesell and Lindquist 2005, Pick et al 2007, Wang et al 2010, Kubota et al 2010). 
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2.3 The structure of Hsp90 
The eukaryotic structure of Hsp90 having 40% similarity with its prokaryotic form (Farrelly and 
Finkelstein 1984, Bardwell and Craig 1987) and is a dimeric phosphoprotein (Spence and 
Georgopoulos, 1989).Hsp90 contains two chaperone-sites, one on its N-terminal domain, and 
other one on the C-terminal domain. There are also other binding sites for calmodulin, peptidyl 
prolyl isomerases and other co-chaperones. Hsp90 forms dimers.ATP binds to its N-terminal 
domain, and changes its conformation. (Minami et al 1994, Prodromou et al 1997, Stebbins et al 
1997, Csermely 1998, Maruya et al 1999) 
Hsp90 contains an ATP binding pocket in Its N-terminal domain, where Geldanamycin binds. 
(Stebbins et al., 1997, Obermann et al 1998, Reviewed by Joachimiak 1997) and yeast Hsp82 
possess an adenine nucleotide binding site (Prodromou et al 1997, revised view in Prodromou et 
al., 2000).  Comparing the structures of N-terminal domain of human Hsp90 without ligand and 
with ATP / AMPPCP was given by Li et al 2012. Human Hsp90 alpha consists of approximately 
732 amino acids, three domains (N-terminal-terminal and middle) and a charge linker. (Huai Q. 
et al 2005, Harris S. F. et al 2004, Dutta R. et al 2000).Co-chaperones and client proteins 
association regulate the ATPase activity of Hsp90 (Whitesell L. et al 2005). 
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Figure 1: Structure of Hsp90 (Adapted from Ref: Whitesell L. et al 2005) 
 
2.4 The Functions of Hsp90 in various biological processes.  
 Hsp90 can efficiently bind to the target proteins and is crucial for their folding, maturation and 
maintaining in the folding competent. (Hartl 1996, Buchner 1999, Csermely et al 1998, Miyata 
and Yahara 1992, Pratt and Toft 1997, Uma et al 1997.Members of Hsp90 binds to various 
peptides in vivo and in vitro .( Menoret et el 1999) Hsp90 involvement in signalling processes, 
poses threat to cellular function.(by Blum et al 2000). Extracellular Hsp90 interacted with the 
receptor CD91 (Basu et al 2001. Cheng et al 2008). Role in disassembly of transcriptional 
complexes: Hsp90 and p23 are recruited to chromatin-bound glucocorticoid receptor; promoter-
bound p23.Hsp90 inhibit GR, TR, NFκB, an AP-1 (Freeman and Yamamoto   2002) 
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Figure 2: The Model of the conformational cycle of Hsp90 (Adapted from Ref: Grossmann 
J. G.  et al 2008) 
 
2.5 Overexpression of Hsp90 in  Breast cancer cells. 
Hsp90 interacts with a number of proteins in breast carcinogenesis. Hsp90 equivalents include 
estrogen receptors, p53 protein, hypoxia-induced transcription factor HIF-1alpha, protein kinase 
Akt, Raf-1 MAP kinase and a number of receptor tyrosine kinases, such as erbB2 (Beliakoff J 
2004).Elevation of Hsp90 expression seems to be a trait of breast cancer and may be one of the 
coping mechanisms that cancer cells exhibit under stress (Conroy SE et al 1996, Yano et al 
1996). It is a promising target for breast cancer therapy (Whitesell L. 2004) High Hsp90 
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expression level is detected in invasive breast carcinomas (Zagouri F 2008) and is associated 
with reduced survival in breast cancer (E Pick 2007) 
2.6 Studies on the interaction between Hsp90 and its client p53. 
 It has been seen that Hsp90 stabilizes p53 mutants (Blagosklonny et al  1995- 1996, Sepehrnia et 
al  1996,Nagata et al 1999,  Whitesell et al  1998) and associated Mdm2, by blocking the E3 
ubiquitin ligase activity of the Mdm2 that can degrade mutant p53.(Peng et al 2001, Li et al  
2011). 
 
Figure 3: Depiction of chaperone interactions that control the function of wild type p53 and 
mutant p53 (Adapted from Ref: Cook P. H. et al 1998) 
In in vitro analysis, hsp90 binds to wild-type p53 in a BAG-1 sensitive fashion (King et al 2001). 
By NMR, p53 core domain is bound to Hsp90, is primarily unstructured (Rüdiger et al 2002). 
Hsp90 Promotes p53 tetramer stabilization and promotes activity of Mdm2 (Burch et al 2004). 
Cancer cells with mutant p53 are more sensitive to Hsp90 and HDAC inhibitors than cells with 
wild type p53 (Li et al 2011).Hsp90 binds and stabilizes native p53 conformation (Müller et al 
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2004, Walerych et al 2004, Hagn et al 2011).It is required for the protection of proteins under 
heat stress and for refolding in collaboration with Hop-Hsp70 (Walerych et al 2009). Release of 
partially unfolded wild-type p53 from Hsp90 is required for promoter binding and dependent on 
ATP binding, but not on ATP hydrolysis (Walerych et al 2010). Interaction of Hsp90 with p53 
has seen in several Hsp90 domains, including the outside of middle domain (Hagn et al 2011). 
The p53 DBD undergoes  loosened molten globule-like state on interaction with the Hsp90 N 
and M domains (Park et al 2011). Others find no evidence of conformational changes, p53 being 
bound in a native state based on shape and charge (Hagn et al 2011). 
 2.7 Hsp 90 Inhibition 
There are various natural and synthetic molecules that have been declared as promising in cancer 
therapy via disrupting the complex of ATP-HSP90-client proteins by targeting hsp90 n-terminal 
ATP binding pocket. Geldanamycin was the first inhibitor that led the way for other inhibitors to 
represent Hsp90 a therapeutic target for cancer therapy. (Schulte et al 1995) Hsp90 binding 
drugs: deoxyspergualin (Nadeau et al 1994) and Geldanamycin and relatives (Whitesell et al 
1994). 
Geldanamycin A and Herbimycin A induce degradation of Raf, receptor tyrosine kinases (Sepp-
Lorenzino et al 1995, Schulte et al 1997), CFTR (Loo et al 1998) through proteasome, and 
transfected nNOS (Bender et al 1999). Cancer cells with mutant p53 are more sensitive to Hsp90 
inhibitors than cells with wild type p53.Oxime derivative of Radicicol with better pharmacology 
(Soga et al 1999). ).Coumarin antibiotics such as Novobiocin bind Hsp90 and reduce levels of 
Hsp90 clients (Marcu et al 2000). Geldanamycin A derivative WX514 .17aag ,17dmag expresses 
much improve results.( Clarke et al 2000,Xu et al 2001, Elizabeth R. Glaze 2005) Geldanamycin 
stimulate association of CHIP with client (erbB2) and facilitates degradation (Xu et al  2002, 
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Zhou et al 2003) and targets tumor cells because of a 100-fold higher affinity of their Hsp90 
complexes (Kamal et al 2003. A review on Hsp90 inhibition to elucidate a new strategy for 
protein kinases has been done. (Sreedhar et al 2004). 
A new class of Hsp90 inhibitors by structure based drug designing has been discovered. (Paul 
Brough 2005). Other novel Hsp90 inhibitors discovered the natural triterpenoids celastrol and 
gedunin, by chemical genomics (Hieronymus et al 2006, Lamb et al 2006). Celastrol interrupts 
Hsp90 interaction with Cdc37 and function without hindering ATP binding (Zhang et al 2008, 
Zhang et al 2009).The involvement of computational biology and the docking studies on 
anticancer drugs has been much helped (Alex Mathew 2009).A review on all Hsp90 inhibitors up 
to date given by HUIFANG HAO 2010, Detailed thermodynamic analysis of drug binding to 
human and yeast Hsp90 (Zubrienė et al 2010). GA/17AAG target VDAC resulting in membrane 
depolarization of mitochondria and increased intracellular Ca2+ (Xie et al 2011).3D structure 
elucidation and macromolecular interactions on hsp90 help in establish drug designing (T. Madej 
2011). 
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 METHODS 
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3. Materials and Methods 
3.1 Tools and bioinformatics softwares used 
3.1.1 Pubchem (pubchem.ncbi.nlm.nih.gov)  
3.1.2  NCBI  
3.1.3 Swissprot  
3.1.4 Expassy tools 
3.1.5  Molinspiron Server 
3.1.6  PHYRE 2 server  (Protein Homology/analogY Recognition Engine) 
3.1.7  Chimera 1.6.1 
3.1.8  PDB(pdb.org)  
3.1.9  Blast  
3.1.10  Clustalw  
3.1.11 Open babel software 2.3.1 
3.1.12  PRODRG 2.5 server(beta)  
3.1.13 Marvin sketch 5.9.1 
3.1.14  Rasmol   
3.1.15  Hex 6.3 
3.1.16 Ligand Scout 3.2  
3.1.17 Molegro virtual Docker 5 
3.1.18  Autodock 4.0 
3.1.19  Ligplot + 1.3.6 and Dimplot 
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3.2  Protocol followed 
       3.2.1 Interaction between Hsp90 and p53 
  Retrieval of amino acid sequences of Hsp90 protein from NCBI 
 
             3D structure of Hsp90 Protein was modeled and obtained by PHYRE server.  
 
            3-D structure of p53, Hsp70, and Hsp40 is retrieved from PDB (Protein Data bank). 
 
 Energy minimization of all 3D structure of proteins had done by Chimera. 
 
              Docking of individual protein and protein complex respectively had done by Hex 6.3. 
 
             Retrieval of the residues involve at the binding site by Dimplot analysis. 
               3.2.2 Inhibition of Hsp90 
  Retrieval of 3D structure Hsp90 domain was from PDB (1YET). 
 
 A collection of small ligand molecule was from Pubchem database.  
 
 OpenBabel 2.3.1 converted all the ligand structures from .sd file format to .pdb format. 
 
 Modification of ligand molecules was by Marvin sketch 5.9.1. 
 
  Energy minimization of ligands  was by Prodrg server. 
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    Docking of hsp90 with all ligands was done by Hex 6.3 and Autodock 4.0. 
 
    Analysis of the binding energy obtained from docking. 
 
    Proposed Pharmacophore model was by LIGAND SCOUT 3.2. 
 
Retrieval of the residues involve in ligand protein interaction by Ligplot 1.3.6 analysis. 
 
3.2.3 Effect of inhibition on binding affinity of hsp90 and p53. 
 Retrieval of the protein-ligand complex was done after Hex docking. 
 
 Docking of the complex with mutant p53 protein structure was by HEX 6.3. 
 
             Analysis of the total energy values changes before and after inhibition. 
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3.3 Methodology 
3.3.1 Retrieval of amino acid sequences of Hsp90 protein from NCBI 
NCBI stands for National Centre for Biotechnological Information. It is established as a 
division of National Library of Medicines at National Institutes of Health. The NCBI  
responsible for creating automated systems  of  knowledge about molecular biology, 
biochemistry, and genetics, providing the use of such databases and software by the research 
and medical community; collect biotechnology information both nationally and 
internationally; and execution research on advanced methods of computer-based information 
processing for examining the structure and function of biologically important molecules. The 
URL for this database is http://www.ncbi.nlm.nih.gov. 
i. The above mentioned URL was browsed. 
ii. In search option, protein was mentioned and hsp90 human was typed. 
iii. There were many results of the search but the accession number AAI21063 was selected 
and the sequences were retrieved in fasta format. 
 
 Figure 4: Retrieval of amino acids from NCBI 
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3.3.2 Retrieval of 3D structure of Hsp90 Protein modeled by PHYRE server. 
PHYRE is an automatic fold recognition server for calculating the structure and function 
of the protein sequence that got submitted in the server. It is used for academic users 
only. It uses the principle and technique of Homology Modeling and relies on Hidden 
Markov Models. 
i. The Fasta format of amino acid sequences was pasted and Phyre 2 search was 
clicked. 
ii. After 5 hours the results were sent to the user given email address. 
iii. The modeled structure was retrieved from the link sent by the server. 
 
 
 
3.3.3 Retrieval of 3-D protein structure of p53, Hsp70, Hsp40 From PDB (Protein Data 
bank). 
The PDB (Protein Data Bank) is the universal store of Structural data of Biological 
macromolecules, founded in Brookhaven National Laboratories (BNL) in 1971.It provides 
Structural information of the macromolecules assessed by X-ray crystallographic, NMR 
Methods. This is very much important as the understanding of shape will lead to the way 
Figure 5: Submission of amino acids in PHYRE server  
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how it functions. As biological macromolecule like protein is having a structure to 
function relationship. Hence an accurate knowledge of structure is needed to know the 
varying functions. This server is free of use.one can easily download the structure in pdb 
file format or fasta format. 
i. The URL www.pdb.org was browsed. 
ii. In the search option Individual protein name was typed. 
iii. After selecting the definite PDB ID, the structure was downloaded and saved in 
.pdb format. 
iv.  Human wild type p53 having PDB ID- 2OCJ, mutant p53 -2QVQ,Hsp90 N-
terminal domain -1YET,Hsp90 middle domain -1HK7,Hsp40-2QLD,Hsp70-3ATU 
were retrieved from protein data bank (PDB). 
3.3.4 Energy minimization of  all 3D structure of proteins  by Chimera 1.6.1. 
 CHIMERA 1.6.1 is an extensible programme for visualization and analysis of molecular 
structure and related data including density maps, supramolecular associations, sequence 
alignments, docking results, routes and conformational ensembles. One of the best 
features is the structural editing job. It can minimize the energy of molecules providing 
them high stability. 
i. Chimera window was opened. 
ii. From the option file, the 3D structure of protein was retrieved. 
iii. The total residues were selected. 
iv. From the tool option, by the structure editing option, minimized structure option 
was clicked. 
v. The minimized structure was saved in .pdb format. 
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3.3.5 Collection of  small ligand molecules from Pubchem. 
Pubchem is a database of chemical structures of small organic molecules and contain 
information of their biological activity, origin and related literatures. It is executed and 
updated by NCBI and is freely available. Millions of compound structures and data seta 
can be freely downloaded in .sd format or chemical (CID) format 
i. Pubchem page was retrieved by browsing pubchem.ncbi.nlm.nih.gov. 
ii.  In search bar  Individual  inhibitors name was typed  & entered  
iii.  All the available ligands of therapeutic target database were retrieved in 
.sd file format. 
iv. The ligands retrieved were Geldanamycin,17dmag,17aag,radicicol,snx-
5422,puc3,curcumin,Herbimycin,witheferin,ATP,novobiocin,Taxol.  
3.3.6  Conversion  of  all the structures from .sd file format to pdb by OpenBabel software 
2.3.1. 
OpenBabel 2.3.1 is a chemical toolkit designed to interpret the various language of 
chemical data. It allows searching, converting, and analyzing chemical data. It supports 
Cheminformatics, molecular modeling, and bioinformatics. It covert chemical data 
from one file format to another. 
i. OpenBabel 2.3.1 window was opened. 
ii. The input format was selected as .sd and the output format as .pdb. 
iii. From the input folder option the .sd files were browsed. 
iv. The output files were generated and saved in the selected folder in .pdb 
format. 
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3.3.7  Modification of ligand molecules by Marvin sketch and properties studied by 
Molinspiron server. 
Marvinsketch is a tool for drawing chemical structures, adding or deleting functional 
group or atoms, queries and reactions. Assigning stereochemistry, charge, valence, 
radicals and isotopes to each atom can be done and moreover single, double, triple 
bonds and aromatic forms can also be created. 
Molinspiration provides a wide range of Cheminformatics tools supporting molecule 
manipulation and processing, SMILES and SD file conversion, normalization of 
molecules, creation of tautomers, molecule disintegration, calculation of several 
molecular properties needed in QSAR, molecular modeling and drug design, high 
quality molecule representation, molecular database tools supporting substructure and 
similarity searches, also support fragment-based virtual screening, bioactivity 
prediction and data visualization. 
i. Marvinsketch window was opened. 
ii. The ligand .pdb format was retrieved. 
iii. Addition, deletion of functional group changes were made keeping in 
mind to increase solubility. 
iv. The new molecules were saved in .pdb format.  
v. The Molinspiron server was opened and ligand .pdb file was uploaded to 
check the bioactivities. 
 
 
 
35 
 
3.3.8 Energy minimization of above ligands by Prodrg server. 
PRODRG takes description of small molecules as pdb/MDL molfile and generate 
variety of topologies that may use for docking and simulations. It works mainly to 
stabilize the ligand molecule by minimizing its energy. 
i.  Prodrg beta server was opened.  
ii.  The pdb format of ligand was pasted in the space provided & run Prodrg. 
iii.  The energy minimized pdb file generated by the server was downloaded and 
saved for future use.  
3.3.9   Docking by Hex 6.3 
Hex 6.3 is an Interactive Molecular graphics program developed by Dave Ritchie for 
estimating docking calculations and displaying docking modes of pairs of protein and 
ligand molecules. HEX is used as the docking tool which calculate intermolecular 
“energies” by adding up all intermolecular interactions (e.g. van der Waals, 
electrostatic) that occur between a ligand and protein target 
i. Hex manual window was opened.  
ii. From the file,   both receptor and ligand separately were opened from the path 
location defined.  
iii. By the option control, docking was selected and activated. 
iv.  Lastly the binding energy (ΔE) produced by docking action was saved 
carefully. 
v. The docking complex was saved from the file option in the .pdb format for 
future analysis. 
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3.3.10  Docking by Autodock 4.0 
Autodock 4.0 is a set of automated docking tools. It is projected to predict how small 
molecules or drug candidates normally bind to a receptor of known 3D structure. 
Autodock include 2 main programs: (I) Autodock executes the docking of the ligand to a 
set of grids describing the target protein and (ii) Autogrid pre-calculates these grids. The 
grid defined is to locate where the ligand can bind. 
i. Before operating Autodock on window 7, first the startup directory path was 
defined. File > preferences > modify defaults >start up directory. 
ii. The receptor molecule and the ligand molecules were saved in the folder location 
defined in directory. 
iii. Autodock window was opened. 
iv. The receptor file was uploaded. File>read molecule>folder> receptor.pdb> open.  
Figure 6: Docking of Hsp90 with mutant p53 by Hex  6.3 
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v. The receptor or the protein molecule was modified. Edit>hydrogens>add. 
vi. The ligand molecule was uploaded. Ligand>input>open>lig.pdb. 
vii. The torsion was set. Ligand>torsion>set no of torsion>”any number”>dismiss 
viii. The ligand was saved in .pdbqt format. Ligand>save>lig.pdbqt>save 
ix. The grid was defined. Grid>macromolecule>open>receptor.pdb>initializing 
ok>protein.pdbqt>save,gridbox>”set coordinates”>file>close saving 
current>output >out.gpf>save 
x. The Autogrid was run. 
xi. The parameters for docking were set. Docking > macromolecule >protein.pdbqt 
>open > ligand > lig.pdbqt >open >accept > search parameters > genetic 
algorithm > 100 >ok > docking parameters > accept > output > Lamarckian 
parameters > dock.dpf >save. 
xii. The Autodock was run for 5 to 6 hours different for different ligands. 
xiii. The result was analyzed. Analyze>dockings>open>dockyyy file, macromolecule 
>open, conformations>play, clustering>show. 
xiv. The energy values and the Ki was calculated and noted down. 
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3.3.11   Ligplot/ Dimplot analyses to interpret the residues and bonds involved 
in binding 
at the binding site. 
                  LIGPLOT is a user friendly programme use to generate protein-ligand interactions                   
                 for a given pdb file encrypting the docking. It shows the interactions facilitated by                                   
                 Hydrogen bonds and Hydrophobic interfaces. 
i. Ligplot window was opened. 
ii. The protein ligand complex.pdb file was opened. 
iii. For protein –ligand interaction, ligplot analysis was done and for protein-
protein interaction Dimplot analysis was done. 
iv. The ligand was selected and the plot window was obtained. 
v. For Dimplot protein chain was selected and the result window was opened. 
vi. The plot was saved. 
 
Figure 7: Docking of Geldanamycin Analogue9 with  Hsp90 by Autodock tool0 by 
Autodock 
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The ten analogoues of Geldanamycin  that are created by Marvin sketch are presented below .. 
 
 
 
 
Figure  8. (a)(b)(c) Represent all the ten analogues of Geldanamycin designed by Marvin sketch 5.9.1 
a 
b 
c 
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4 Results and Discussion  
4.1  Interaction between Hsp90 and p53 
 
The Hsp90 structure was modeled, aligned, and compiled in one full length 3D structure. This 
structure contains all the three domain:N-terminal,middle and C-terminal domain. The spiral look in 
the structures are α- helices and the arrow ones are β-sheets. 
  
 
 
4.1.1 HEX 6.3 Docking Results (protein - protein) 
The whole docking procedure has been done sequentially. First the Hsp90,Hsp70,and Hsp40 docked 
with wild type p53 and mutant p53 respectively. Then the complex of Hsp90-Hsp40,Hsp90-
Hsp70,Hsp40-Hsp70,Hsp90-Hsp40-Hsp70 docked with wild type p53 and Mutant Type p53 
separately. First the Hsp90 N-terminal domain was used, then followed the middle domain and the 
whole hsp90 full length. The docking results are summarized in Table 1.The findings of the results 
are solely based on the docking energy value and the interaction at the binding sites. The more 
negative the value, the more stable the complex is and more binding affinity. According to the energy 
Figure 9: Modeled 3D structure of Hsp90 α by PHYRE 2 server 
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funnel theory less energy depicts highly stable conformation. Hence more energy would be needed to 
break the complex that means high dissociation energy. 
Complex Wild type p53 Mutant p53 Docking Energy 
 
Hsp90 
 
+ - - 1170.86 
- + - 630.94 
 
Hsp40 
 
+ - - 842.79 
- + - 695.12 
 
Hsp70 
 
+ - - 968.13 
- + - 760.47 
 
Hsp90 + Hsp40 
 
+ - - 736.82 
- + - 708.89 
 
Hsp90 +Hsp70 
 
+ - - 593.33 
- + - 720.32 
 
Hsp40 +Hsp70 
 
+ - - 497.14 
- + - 801.13 
 
Hsp90+Hsp70+Hsp40 
 
+ - - 643.65 
- + - 834.01 
   
 
 
Table1: Hsp90 N-terminal domain docking calculation by Hex 6.3 online server 
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The interpretation of the results of Table 1 is summarized below. 
The docking energy of Hsp90- wild type p53 complex is -1170.86 kcal/mol and that of Hsp90 and mutant 
p53 complex is -630.94kcal/mol .This infer the high binding affinity of Hsp90 towards wild type p53 than 
mutant type p53.The Hsp90-wild type p53 complex is more stable. 
The docking of Hsp40 individually or in complex form with wild type p53 came to be more stable. 
The Hsp90-Hsp40-Hsp70 complex docked with wild type p53 showed energy value -643.65 kcal/mol and 
with mutant p53 showed -834.01 kcal/mol. Hence in complex form Hsps form stable complex with 
mutant p53 than wild type p53. 
This interpreted that the chaperone complex activity of Hsps may involve in cancer 
. 
Complex 
Wild type p53 
 
       Mutant p53 Docking Energy 
 
Hsp90 middle domain 
 
+  - - 541.06 
- + -686.62 
Hsp90 full length   + - - 63.10 
         - + -668,62 
 
 
Hsp90 other domain showed in Table 2, forming more stable complex with mutant p53 than the wild 
type p53.Hence there remained a strong association of Hsp90 with mutant p53.Hence proved the 
literature view of expression and involvement of Hsp90 in cancer. The results also proved the 
interaction between the Hsp90 and its client Protein p53. 
Table 2:Hsp90 other domain docking calculations. 
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4.1.2 Results of Dimplot Analysis (for protein-protein interactions) 
The dotted line shows the hydrogen bonding ,distance between the residues, the maroon color depict 
the residues of Hsp90 and the pink color depict the p53 residues(both Polar and non-polar).    
 
 
 
Full length hsp90 and mutant p53 
Figure 10: The Dimplot plot analysis of Full length Hsp90 and mutant p53.  
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Figure 11: The Dimplot analysis of Hsp90 chain A interacting with mutant p53 chain A. 
Figure 12: The Dimplot analysis of Hsp90 interacted with wild type p53 
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Figure 13: The Dimplot analysis of Hsp90 interacted with wild type p53. (chain A-chain B) 
The results of Dimplot analysis are summarized below. 
 The  hydrophobic residues of Hsp90 involved in the interaction with wild type p53 are 
Phe20,Glu18,Asp259,Ser 106,Leu198,Glu 196,Thr 195,Asp87 and the hydrophobic residues of 
wild type p53 are Arg 183,Ala 270,Lys120,Thr 140,Ser121. 
The residues involved in hydrogen bonding are put down in Table 3. 
Hsp90 residues Wild type p53 Distance measured in Angstrom 
Glu 16 Cys 182 3.20 
Val17 Ser 183 1.41 
Lys 84 Lys 139 3.13 
Glu192 Thr 123 1.92 
 
                 Table 3: The residues involved in binding of Hsp90-Wildtype p53  generated and the distance 
measured by Dimplot 
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The hydrophobic residues of Hsp90 that interacted with Mutant p53 are Arg 620,Tyr 38,Tyr 
528,ser 406,Lys209,Glu 451,tyr 528,Arg 413,Lys 263,Glu180,Thr 269,Tyr 222 and the residues of 
p53 involved are Asp222,Gly112,Leu 289,Gln144,Tyr 126,Ala 119,Val 122.Thr 182 etc. 
The residues involved in Hydrogen bonding are depicted in Table 4. 
Hsp90 residues Mutant p53 Distance measured in Angstrom 
Lys 41 Glu 287 3.36 
Asn 40 Glu 286 3.03 
Ser39 Thr118 3.00 
Thr 36 His 115 3.19,1.45 
Lys 357 Glu 271 1.39 
Arg 355 Asn 247 3.11 
Gln 261 Leu 111 2.74 
Gln 261 Trp 146 2.20 
Thr 332 Cys 124 1.85 
Ser 182 Gln 104 1.86 
Gly 277 Thr 118 3.19 
Lys 218 Glu 286 2.35 
Lys 275 His 115 2.05 
Ser 272 His 115 2.59 
   
Table 4: The residues involved in binding of Hsp90-Mutant p53  generated and the distance 
measured by Dimplot 
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   The above findings proved the interaction of Hsp90 and p53 (both wild and mutant), the residues 
involved at the binding interface and the distance measured. 
4.2 Inhibition of Hsp90 
 
The ATPase fold or the Bergerat fold on the Hsp90 N-terminal Domain has been targeted for 
inhibitory studies. From the Literature view point ten ligand molecules selected, keeping 
ATP molecule as control. As previously stated the lower the energy Value, the stronger the 
binding association would be. All the selected ligands were docked with Hsp90 to compete 
ATP molecule and the results are shown in Table5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligand Molecules 
 
 
E-Value 
ATP -262.78 
Herbimycin -313.71 
Radicicol -231.21 
Withaferin -276.85 
Curcumin -269.08 
PU3 -257.70 
Snx-5422 -293.94 
Geldanamycin -315.36 
17AAG -308.96 
17DMAG -311.70 
Table 5: The docking energy calculations targeting Hsp90 by Hex 6.3 
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The docking of ligands was carefully observed and their interaction and orientations were also 
monitored. Table 5.  result showed that Geldanamycin having highest binding affinity (-
315.36),second to that Herbimycin also scored high (-313.71) and third one the Geldanamycin 
derivative 17DMAG scored good (-311.70).All the ligands except PU3 and Radicicol showed 
high binding affinity than the ATP molecule ,which was kept as control to row down the 
analysis. Hence these ligands having high affinity than ATP can be used as Hsp90 inhibitors. As 
the ligands are more competent than ATP molecule, that’s why when they will enter the cytosol, 
they may replace ATP and would bind the catalytic site of Hsp90 which will further interrupt its 
chaperoning function. 
 
 
The residues of Hsp90 involved in docking to Geldanamycin  at the binding interface are shown 
in figure 6.The residues primarily involved in hydrogen bonding are Phe138,Asp 93,Thr 184,Lys 
Figure 14: Showed the residues of Hsp90 interacted with Geldanamycin at the binding interface by Ligplot 
analysis. 
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58 and hydrophobic ones are Val136,Gly137,Asp54,Ile96,Asn106,Ala 58,Met98,Leu 107 and 
Val180.The residues that formed hydrogen bonding are confirmed to be present at or on the 
binding cavity, Hence these residues would consider to be as specific ones which would involve 
in any further ligand binding as they are on the binding interface. Thus the four fate determining 
residues for other ATPase fold binders are Phe 138, Thr 184, Lys58 and Asp 93. 
  Now, the result showed Geldanamycin is a potent inhibitor that got matched with the literature 
studies. According to the research works on Geldanamycin stated that it couldn’t enter into the 
clinical trials because of its poor solubility and toxicity. The reason may be the solubility. As we 
know Animal cells are more aqueous in nature, hence water soluble substances easily soluble in 
cytosol and water insoluble form precipitates. And any extra thing in the cytosol leads to cell 
toxicity. This is why all the research works are going on to modify Geldanamycin structure to 
increase its solubility. This thought inspired us to work on the modification of Geldanamycin 
structure. With the help of Marvinsketch, ten analogues were made keeping in mind that it will 
increase solubility. Hence the functional groups that enhance solubility are –COOH,-OH,-NH, 
and the functional groups enhance electronegativity that will help in hydrogen bonding. Hence at 
different position the changes were made randomly with the functional group and somewhat hit 
and trial method. All the structures were tested for their bioactivity and properties on 
Molinspiron server. 
The docking calculations were made by Hex 6.3 and tabulated in Table 6.The results showed the  
binding affinities of the Geldanamycin analogues .According to Hex docking Analogue 2  scored 
high i.e. -286.20,it mean it has high binding affinity than the others. Other analogues scored high 
referring to the control ATP molecule. The analogues showed good binding affinity than ATP 
molecule. Figure 6 showed the binding cavity of Hsp90, where Analogue 2 was bound. Figure 7 
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depict the map of Analogue 2 interaction on Hsp90 binding cavity. The residues involved in the 
interactions are Asn51, Phe138, Asp93, Ala55, Met98, Thr184, Ile 96, Leu107 and Lys112 of 
Hsp90 at the binding interface. The residues matched with the control that have chosen before in 
figure6 are Asp93, Thr184 and Phe138.Hence it is confirmed that Geldanamycin analogue 2 bind 
to the active site. 
Geldanamycin Analogues E-Value 
Analogue 1 -266.17 
Analogue 2 -286.20 
Analogue 3 -270.16 
Analogue 4 -267.51 
Analogue 5 -270.26 
Analogue 6 -276.07 
Analogue 7 -275.75 
Analogue 8 -270.26 
Analogue9 -265.27 
Analogue 10 -277.57 
. 
Table 6: The docking energy calculations of Geldanamycin Analogues by HEX 6.3 
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Figure 15: Geldanamycin Analogue 2 bind to the binding cavity of Hsp90 by Molegro Virtual Docker  
Figure 16: Analogue 2 –Hsp90 interaction map by Ligand scout 
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Geldanamycin and its Analogues 
 
E-Value 
Kcal/mol 
 
Ki-Value 
Geldanamycin -9.56 97.80nm 
Analogue 1 -9.63 86.99nm 
Analogue 2 -7.75 2.08µm 
Analogue 3 -9.20 180.94nm 
Analogue 4 -8.15 1.07 µm 
Analogue 5 -9.60 91.88nm 
Analogue 6 -9.49 110.65nm 
Analogue 7 -9.44 120.26nm 
Analogue 8 -9.50 108.56nm 
Analogue 9 -9.64 85.75nm 
Analogue 10 -9.03 239.99nm 
 
 
All the analogues modified were docked with Hsp90 by Autodock 4.0 version tool. Autodock is a 
promising tool in drug designing and docking and the work is done manually. All forms of docking, rigid, 
flexible and semi flexible docking can be done .Hence all the analogues were docked for 10, 50 and 100 
conformations respectively. First the grid was made on whole domain to check where it is binding other 
than active site, and then the grid was restricted around the active site and docked. The Autodock 4.0 
results varied from Hex 6.3 results. Autodock 4.0 analysis showed three analogues that outscored original 
Geldanamycin. Analogue 5 (-9.60 kcal/mol), Analogue 1 (-9.63 kcal/mol), Analogue 9 (-9.64) scored 
high that means they have high binding affinity than the original Geldanamycin. 
Table 7: The docking calculations of Geldanamycin and its analogues were by Autodock 4.0 version. 
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On the basis of Ki calculation all the three mentioned ligands scored better results. Ki is the inhibition 
constant. It is the concentration required to produce half maximum inhibition. Hence if Ki is low, then, 
cytotoxicity would be low. Considering all the above facts Analogue 9 came out to be the best one.  
 
Figure 17: the hydrophobic interaction of Geldanamycin Analogue 9 at the binding cavity of Hsp90 by Ligplot 
analysis 
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Figure 18: Pharmacophore modeling by Ligand scout 
Figure 19: Ligand scout analysis of Geldanamycin Analogue9. 
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As the Analogue 9 showed good results, we followed to fulfill the demand of controls that 
have been set primarily. Figure 9 depicted the Pharmacophore modeling to enhance the 
binding affinity. The results of ligplot in Figure 8 and ligand scout in figure 10 added 
confirmation. It has been shown that the residues that involved in interaction with Analogue 
9 include Asp93, Lys58, Thr184 and Phe138.Hence analogue 9 bind to the catalytic site of 
Hsp90 and having good affinity than the original making it a potential ligand for future uses. 
4.3 Effect of inhibition on binding affinity of hsp90 and p53. 
Previously the findings showed good affinity between Hsp90 and mutant p53 which worked 
in a chaperoning complex. For other individual domain docking with Mutant p53 established 
that Hsp90 is the culprit to protect its mutant form. Hence Again the Inhibition studies have 
undergone and some suitable candidate are found along with the Literature‘s best ones. Now 
To add some more spices to the study, the full length structure of Hsp90 comprising all the 
domains has been taken. Here Mutant p53 docked with the full length Hsp90 without any 
inhibitors and with specific inhibitors to analyze the consequences. All these studies were 
based on docking energy calculation by hex only. 
Complex Mutant p53 E-Value 
Hsp90 + -668.62 
Hsp90 +17DMAG + -619.82 
Hsp90 +Analogue 5 + -568.79 
Hsp90 +Analogue 2 + - 649.87 
Hsp90 +Analogue 9 + - 650.64 
 
 
Table 8: Docking calculation between Hsp90 and mutant p53 after Hsp90 inhibition 
57 
 
The Table 8 summarized all the docking calculations and inferred the differences of docking 
energy before and after inhibition. Before inhibition the binding energy was -668.62 and after 
inhibition it has been changed accordingly with respect to the inhibitors docked. The energy 
value changed to less negative. As previously stated the more negative e-value the more the 
stable the complex would. Now according to that the stability of p53-Hsp90 binding complex 
became weaker upon inhibition. The reason may be due to the conformational changes of Hsp90 
made by the inhibitor. When the inhibitor bind to the Hsp90 N-terminal domain, there must be 
some conformational changes to Hsp90 structure, because of which it had failed to form a stable 
complex with mutant p53.And this is what we needed, that means the inhibition not only 
interrupting catalytic activity but also inducing the conformational changes. Thus the objective 
set from the start of this work seems to be fulfilled computationally. 
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5.1  Conclusions 
Protein-protein interactions and protein –ligand interactions play a crucial role in biological 
functions.Hsp90.The results stated that Hsp90 alone is not responsible for its chaperoning 
activity and malignancy but moreover it’s a chaperoning complex with Hsp70 and Hsp40 that 
works simultaneously. Different domains of Hsp90 showed different affinity towards p53 (both 
wild type and mutant).Hsp90 showed more affinity towards wild type p53 as the docking 
calculations made by hex 6.3 i.e. -1170.76 kcal/mol, while in complex with Hsp70 and hsp40 
expressed high affinity towards mutant p53 i.e. -834.01.Also the results of Ligplot analysis 
visualized the residues involves in hydrogen bonding, hydrophobic interaction and even the 
distance between the residues is found to be in angstrom unit. These finding confirmed the 
establishment of Hsp90 and its client p53 interaction and Involvement of the multi chaperoning 
complex in mutant p53 stability. Inhibition of Hsp90 may interrupt its chaperoning function as 
stated in all literatures. Here Geldanamycin is found to be a potent inhibitor  among all the 
chosen ligands which scored high (-315.36 kcal/mol) on docking calculations made by Hex 
6.3.As the literatures stated about its toxicity and poor solubility ,Geldanamycin was modified by 
Marvinsketch and formed 10 Analogues. Upon docking the analogues with Hsp90 by Hex, 
Analogue 2 scored high (-286.20 kcal/mol) but not better than original one. But upon docking by 
Autodock, Analogue 9 scored the best (-9.64kcal/mol) even better than original Geldanamycin. 
Other Analogue 5 (-9.60kcal/mol) and Analogue 1 (-9.63 kcal/mol) showed good results than 
original Geldanamycin (-9.53 kcal/mol).Also in terms of Ki (Inhibition constant) calculation all 
the three outnumbered Geldanamycin by exhibiting less concentration for inhibition. Ki is the 
concentration at which half of the maximum inhibition occurs. If the Ki is less that means less 
concentration can do the inhibition, and which means less cytotoxic and side effects of the ligand 
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molecules.  Again the docking results of the inhibited Hsp90 complex with mutant p53 explicit 
the decrease in binding affinity between the Hsp90 and Mutant p53.It lead to make the 
assumption that may be the inhibitor upon inhibition changes the conformation of Hsp90 
,because of which the affinity goes down. There may be some changes in conformation so that 
the mutant p53 could not bind to Hsp90 with higher affinity. The above said results clearly stated 
that not only the inhibitor inhibited its catalytic activity but also interrupt its chaperoning action 
by interfering in the interaction between Hsp90 and Mutant p53. 
5.2 Future perspectives 
All the above findings are established with the help of promising, highly developed and reliable 
tools and software of computational biology. In this modern era of Insilco, every work is first 
tested by Virtual screening or Insilico designing, then only it goes for invitro and invivo analysis. 
The protocol follows like Insilico designing, Insitu designing, Invitro analysis and final invivo 
analysis. Likewise analogue 2 and Analogue 9 should undergo QSAR analysis and further the 
whole complex should be studied under molecular dynamic simulations. This would put the 
above findings in real dynamics to see the changes. And after simulation it can further go for 
invitro analysis.Hsp90 as a therapeutic target is not new but it shows new exciting results. 
The crucial biological functions performed  by HSP90 and the  dependency of cancer cells on the 
marked functions of Hsp90 make itself as an attractive target for anti-cancer chemotherapeutics. 
Among the trademarks of cancer, up-regulation of growth signals and apoptotic interruption are 
the most vital. As maximum growth signals rely on Hsp90 for their functional stability, Hsp90 
become an ideal molecule to interfere in complicated web of oncogenic pathways. Therefore, 
drugs targeting Hsp90 are more advantageous than the oncogene pathway inhibitors. 
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